Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Operating Leases (2019 - 2025)

Sunshine Biopharma (SBFM) has disclosed Operating Leases for 5 consecutive years, with $636708.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 44.61% year-over-year to $636708.0, compared with a TTM value of $636708.0 through Sep 2025, up 44.61%, and an annual FY2024 reading of $744724.0, up 38.16% over the prior year.
  • Operating Leases was $636708.0 for Q3 2025 at Sunshine Biopharma, down from $706530.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $744724.0 in Q4 2024 and bottomed at $440298.0 in Q3 2024.
  • Average Operating Leases over 4 years is $596439.4, with a median of $604993.0 recorded in 2023.
  • The sharpest move saw Operating Leases fell 22.44% in 2024, then surged 52.63% in 2025.
  • Year by year, Operating Leases stood at $642232.0 in 2022, then fell by 16.07% to $539035.0 in 2023, then soared by 38.16% to $744724.0 in 2024, then dropped by 14.5% to $636708.0 in 2025.
  • Business Quant data shows Operating Leases for SBFM at $636708.0 in Q3 2025, $706530.0 in Q2 2025, and $722199.0 in Q1 2025.